The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy of bevacizumab plus erlotinib (B+E) in patients (pts) with renal medullary carcinoma (RMC).
 
Andrew James Wiele
No Relationships to Disclose
 
Devaki Shilpa Surasi
No Relationships to Disclose
 
Priya Rao
No Relationships to Disclose
 
Kanishka Sircar
No Relationships to Disclose
 
Tharakeswara Bathala
No Relationships to Disclose
 
Amishi Yogesh Shah
Honoraria - Eisai; Oncology Information Group
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Pfizer/EMD Serono
Research Funding - Bristol-Myers Squibb; Eisai; EMD Serono
 
Eric Jonasch
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Ipsen; Novartis; Pfizer
Research Funding - Exelixis; Novartis; Peloton Therapeutics; Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Vince David Cataldo
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Giannicola Genovese
No Relationships to Disclose
 
Jose A. Karam
Stock and Other Ownership Interests - Alimera Sciences; MedTek
Honoraria - Pfizer; Roche/Genentech
Consulting or Advisory Role - Pfizer; Roche/Genentech
Research Funding - Merck (Inst); Mirati Therapeutics (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech
 
Christopher G. Wood
No Relationships to Disclose
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Lilly; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Nektar; Neoleukin Therapeutics; Novartis; Oncorena; Ono Pharmaceutical; Pfizer; Surface Oncology
Research Funding - Arrowhead Pharmaceuticals; Bristol-Myers Squibb; Calithera Biosciences; Eisai; Epizyme; Exelixis; Lilly; Mirati Therapeutics; Nektar; Pfizer; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Nektar; Neoleukin Therapeutics; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer; Surface Oncology
 
Pavlos Msaouel
Honoraria - Bristol-Myers Squibb; Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Mirati Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)